Close
  Indian J Med Microbiol
 

Figure 5: Effects of Astragalus polysaccharides on the toll-like receptor 4 expression. Dampness stagnancy due to spleen deficiency rats was treated with Astragalus polysaccharides for 14 days, and toll-like receptor 4 expression was determined by quantitative real-time polymerase chain reaction and immunohistochemistry (a and b, respectively). The representative images are showed in the control group (b1), dampness stagnancy due to spleen deficiency group (b2), Shen Ling Bai Zhu San group (b3), and Astragalus polysaccharides groups (b4-b6). Data are expressed as mean ± standard deviation for three animals in each group, ##P < 0.01 the control group and Astragalus polysaccharides-treated group compared with the dampness stagnancy due to spleen deficiency group (a); *P < 0.05, **P < 0.01 between the control and the dampness stagnancy due to spleen deficiency group, #P < 0.05, ##P < 0.01 between the dampness stagnancy due to spleen deficiency group and drug-treated group (b)

Figure 5: Effects of Astragalus polysaccharides on the toll-like receptor 4 expression. Dampness stagnancy due to spleen deficiency rats was treated with Astragalus polysaccharides for 14 days, and toll-like receptor 4 expression was determined by quantitative real-time polymerase chain reaction and immunohistochemistry (a and b, respectively). The representative images are showed in the control group (b1), dampness stagnancy due to spleen deficiency group (b2), Shen Ling Bai Zhu San group (b3), and Astragalus polysaccharides groups (b4-b6). Data are expressed as mean ± standard deviation for three animals in each group, <sup>##</sup><i>P</i> < 0.01 the control group and Astragalus polysaccharides-treated group compared with the dampness stagnancy due to spleen deficiency group (a); *<i>P</i> < 0.05, **<i>P</i> < 0.01 between the control and the dampness stagnancy due to spleen deficiency group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.01 between the dampness stagnancy due to spleen deficiency group and drug-treated group (b)